Substantial progress across Xeltis’ restorative cardiovascular device platform will be illustrated in two presentations at the International Society for Applied Cardiovascular Biology (ISACB) 2022 meeting this week. Xeltis CTO, Martijn Cox, will present the advancements of clinical trials on XPV, the Xeltis restorative pulmonary valve, and Mohammed El-Kurdi, Xeltis Vice-President for Vascular R&D, will showcase the most recent clinical and pre-clinical results of Xeltis small-diameter grafts for Coronary Artery Bypass Graft (CABG) – the XABG, and of the hemodialysis vascular access graft, aXess.
The Xeltis technology has shown remarkable results across trials and, with three products in clinical phase, it is the most advanced polymer-based platform of restorative cardiovascular devices. Xeltis’ products are restorative, synthetic, biocompatible and absorbable electrospun devices that turn into living blood vessels and heart valves when colonized by patient’s own tissue cells.
“The success of endogenous tissue restoration has been demonstrated in both preclinical and clinical settings, across a wide range of cardiovascular applications,” said El-Kurdi, “suggesting that Xeltis has developed a tunable and robust tissue restoration platform”.
The International Society for Applied Cardiovascular Biology (ISACB) is devoted to enhancing discovery, development and clinical translation of cutting-edge biomedical science for innovative, state of the art cardiovascular diagnostic and therapeutic modalities. The ISACB 2022 meeting is taking place in Memphis (TN, USA) from September 28 to October 1.
